Marengo Therapeutics

Today Marengo Therapeutics announced?a clinical study collaboration with Gilead Sciences to evaluate Marengo’s Invikafusp alfa (STAR0602) and Gilead’s Trodelvy? in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers.? ? The collaboration will evaluate the combination of Marengo’s first-in-class TCR Vb selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead’s Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002). This innovative combination approach will leverage two unique modalities to target and potentially eradicate cancer cells. Read our press release to learn more:?https://lnkd.in/e6kX7Nhb

It's official! ??Marengo Therapeutics has been featured on Fortune’s "2024 Best Small & Medium Workplaces in BioPharma" list! ?? #greatplacetowork #BestWorkplacesBioPharma #GPTWcertified

Fall is here and September has started off with a bang – today we are welcoming Camelia Raize and Yanfeng Zhou to the Marengo team. We are thrilled to have you with us! ? ?Check out our current open roles: https://lnkd.in/eQCzHw7z

Please welcome Srinjoy Chakraborti, PhD, who joined Marengo earlier this July. We are ecstatic to have you with us! ? Check out our current open roles: https://lnkd.in/eQCzHw7z

Earlier this month, Marengo’s research team embarked on a helpful offsite team-building event, graciously hosted by Claria Partners . During this event, we delved into our Insights Discovery results. The Insights Discovery tool uses a 4-color model to help people understand their style, their strengths, and the value they bring to the team. ? As the final group at Marengo to undergo this process, our scientists were eager to uncover their results and compare them with those of their colleagues. It came as no surprise that "cool blue" emerged prominently among our team. ? Our heartfelt thanks to Claria Partners for orchestrating such a valuable and insightful event. Many of our team members continue to reflect on the profound insights gained.

This summer, we’ve been extremely fortunate to have Keana Ramos Baptista on our team. Keana, who is about to enter her junior year at Boston University, has spent the past few months assisting the Marengo team in the office and the lab. Her contributions have made her an invaluable member of our People & Culture team. We met Keana through Project Onramp , a wonderful program by Life Science Cares Boston. We are truly grateful for the dedication and enthusiasm she has brought to her internship. We are excited to see all the amazing things Keana will accomplish in the future and wish her the very best. Learn more about the program here: https://projectonramp.us

Attending DIA (Drug Information Association)'s Global Annual Meeting in San Diego? Join Marengo's Chief Development Officer Ke Liu , MD, PhD for their panel session to interpret FDA guidance, discuss trends, and share their own experiences for study design in cell and gene therapy trials.

Wonderful discussion on expediting the #platform to #pipeline journey with Leslie J Williams HC Bioscience, Inc., Rachel W. Humphrey, MD Normunity, Geoffrey McDonough Generation Bio, Mittul Mehta TEVOGEN BIO, Zhen Su, MD MBA Marengo Therapeutics at #longwoodhealthcareleaders Longwood Fund

What an honor to host Brad Loncar (BiotechTV) on site at Marengo Therapeutics and chat about our recent $1.2B partnership with Ipsen focused on our next generation Precision T-cell engager approach to bring more targeted IO therapeutics to "COLD" tumor. Let's to it together as One Team!

?? Nasdaq celebrates the extension of the strategic partnership between Marengo Therapeutics and Ipsen! This collaboration continues to drive innovation and growth in the biotech sector for better treatment for patients, setting new standards for success. ?? A special thanks to the Nasdaq team for this honor!?ATP (Apple Tree Partners) #Nasdaq #Marengo #Ipsen #Biotech #Partnership #oncology